Filing Details

Accession Number:
0001209191-21-019957
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-11 19:35:16
Reporting Period:
2021-03-09
Accepted Time:
2021-03-11 19:35:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1564824 Allakos Inc. ALLK () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198325 Daniel Janney Four Embarcadero Center
Suite 2100
San Francisco CA 94111
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-09 100 $125.00 103,534 No 4 S Indirect By Alta Bioequities L.P.
Common Stock Disposition 2021-03-11 6,006 $124.62 97,528 No 4 S Indirect By Alta Bioequities L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Alta Bioequities L.P.
No 4 S Indirect By Alta Bioequities L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,519,200 Indirect See Footnote
Footnotes
  1. Reflects distributions in kind effected by Alta Partners VIII, L.P. ("Alta VIII") and Alta Partners NextGen Fund I, L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.
  2. Consists of 2,071,147 shares held of record by APNG I and 6,448,053 shares held of record by Alta VII.
  3. The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The Reporting Person is a managing director of Alta Management VIII and, as such, may be deemed to share voting and investment control with respect to the shares held by Alta VIII. The Reporting Person disclaims beneficial ownership of all shares held by Alta VIII, except to the extent of his pecuniary interest therein.
  4. The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein.
  5. Shares held prior to the reported transaction consisted of an aggregate of 103,634 shares received in pro rata distributions from APNG I and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.
  6. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.25 - $125.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.